Posted by Michael Wonder on 18 Jan 2017
Suliqua approved in the European Union for the treatment of adults with type 2 diabetes mellitus
17 January 2017 - Sanofi announced today that the European Commission has granted marketing authorisation in Europe for Suliqua, the once-daily titratable fixed-ratio combination of basal insulin glargine 100 units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes.
Suliqua is authorised for use in combination with metformin to improve glycemic control when this has not been provided by metformin alone or metformin combined with another oral glucose lowering medicinal product or with basal insulin.
